RxDoctor Payments Data

Thomas Dukovac, MD

Urology · Thibodaux, LANPI 1548641061

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 51 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$175
  • Cook Medical LLC$167
  • Astellas Pharma US Inc$93
  • Progenics Pharmaceuticals, Inc.$80
  • Coloplast$63
  • Pfizer$56
  • plus $552 from 16 others

What the payments were for

  • Food & beverage$1,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,186 in reported general payments places this provider in the 25th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$121,481
Medicare patients
225
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron48$29,223
MyrbetriqMirabegron34$26,762
Tamsulosin Hcl379$4,314
Potassium Citrate ErPotassium Citrate40$2,363
Finasteride142$2,001
Estradiol16$1,078
Ciprofloxacin Hcl34$365
Indapamide20$246
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$142
Ibuprofen59$125
Oxybutynin Chloride ErOxybutynin Chloride12$113
Oxybutynin Chloride21$105
Tramadol Hcl12$19

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$40$29,22348 claims
Astellas Pharma US IncMyrbetriq$93$26,76234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 199 urology providers in Louisiana.

Other urology in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →